

# Jean-Pierre Rab s

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2976806/publications.pdf>

Version: 2024-02-01

18  
papers

3,161  
citations

858243

12  
h-index

993246

17  
g-index

18  
all docs

18  
docs citations

18  
times ranked

4498  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of familial hypercholesterolaemia in patients presenting with premature acute coronary syndrome. <i>Archives of Cardiovascular Diseases</i> , 2022, 115, 87-95.	0.7	5
2	Whole Exome/Genome Sequencing Joint Analysis of a Family with Oligogenic Familial Hypercholesterolemia. <i>Metabolites</i> , 2022, 12, 262.	1.3	1
3	APOE Molecular Spectrum in a French Cohort with Primary Dyslipidemia. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5792.	1.8	4
4	Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis. <i>Medical Science Monitor</i> , 2021, 27, e928784.	0.5	3
5	APOE gene variants in primary dyslipidemia. <i>Atherosclerosis</i> , 2021, 328, 11-22.	0.4	60
6	Identification of a Variant in APOB Gene as a Major Cause of Hypobetalipoproteinemia in Lebanese Families. <i>Metabolites</i> , 2021, 11, 564.	1.3	5
7	A Simple RFLP-Based Method for HFE Gene Multiplex Amplification and Determination of Hereditary Hemochromatosis-Causing Mutation C282Y and H63D Variant with Highly Sensitive Determination of Contamination. <i>BioMed Research International</i> , 2020, 2020, 1-6.	0.9	0
8	New Sequencing technologies help revealing unexpected mutations in Autosomal Dominant Hypercholesterolemia. <i>Scientific Reports</i> , 2018, 8, 1943.	1.6	25
9	Usefulness of the genetic risk score to identify phenocopies in families with familial hypercholesterolemia?. <i>European Journal of Human Genetics</i> , 2018, 26, 570-578.	1.4	22
10	Familial hypercholesterolemia. <i>Current Opinion in Lipidology</i> , 2018, 29, 65-71.	1.2	24
11	High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry. <i>Atherosclerosis</i> , 2018, 277, 334-340.	0.4	33
12	Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015). <i>Expert Opinion on Therapeutic Patents</i> , 2016, 26, 1377-1392.	2.4	23
13	Exome Sequencing in Suspected Monogenic Dyslipidemias. <i>Circulation: Cardiovascular Genetics</i> , 2015, 8, 343-350.	5.1	45
14	Characterization of Autosomal Dominant Hypercholesterolemia Caused by <i>PCSK9</i> Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody. <i>Circulation: Cardiovascular Genetics</i> , 2015, 8, 823-831.	5.1	90
15	Living the PCSK9 Adventure: from the Identification of a New Gene in Familial Hypercholesterolemia Towards a Potential New Class of Anticholesterol Drugs. <i>Current Atherosclerosis Reports</i> , 2014, 16, 439.	2.0	87
16	Description of a Large Family with Autosomal Dominant Hypercholesterolemia Associated with the <i>APOE</i> p.Leu167del Mutation. <i>Human Mutation</i> , 2013, 34, 83-87.	1.1	103
17	Molecular Spectrum of Autosomal Dominant Hypercholesterolemia in France. <i>Human Mutation</i> , 2010, 31, E1811-E1824.	1.1	99
18	Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. <i>Nature Genetics</i> , 2003, 34, 154-156.	9.4	2,532